Akebia Therapeutics Stock Cash Per Share
| AX9 Stock | 1.93 0.02 1.05% |
Akebia Therapeutics fundamentals help investors to digest information that contributes to Akebia Therapeutics' financial success or failures. It also enables traders to predict the movement of Akebia Stock. The fundamental analysis module provides a way to measure Akebia Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Akebia Therapeutics stock.
Akebia |
Akebia Therapeutics Company Cash Per Share Analysis
Akebia Therapeutics' Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
| Competition |
In accordance with the recently published financial statements, Akebia Therapeutics has a Cash Per Share of 0.0 times. This indicator is about the same for the average (which is currently at 0.0) sector and about the same as Cash Per Share (which currently averages 0.0) industry. This indicator is about the same for all Germany stocks average (which is currently at 0.0).
Did you try this?
Run CEOs Directory Now
CEOs DirectoryScreen CEOs from public companies around the world |
| All Next | Launch Module |
Akebia Fundamentals
| Current Valuation | 12.46 M | |||
| Price To Book | 3.97 X | |||
| Price To Sales | 0.18 X | |||
| Revenue | 213.58 M | |||
| EBITDA | (227.35 M) | |||
| Net Income | (282.84 M) | |||
| Cash Flow From Operations | (252.97 M) | |||
| Market Capitalization | 387.3 M | |||
| Total Asset | 525.55 M | |||
| Net Asset | 525.55 M |
About Akebia Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Akebia Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Akebia Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Akebia Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Akebia Stock Analysis
When running Akebia Therapeutics' price analysis, check to measure Akebia Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Akebia Therapeutics is operating at the current time. Most of Akebia Therapeutics' value examination focuses on studying past and present price action to predict the probability of Akebia Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Akebia Therapeutics' price. Additionally, you may evaluate how the addition of Akebia Therapeutics to your portfolios can decrease your overall portfolio volatility.